Gopten

Gopten is a medication that contains the active ingredient trandolapril, an ACE inhibitor, supplied in oral form. It is marketed in the European Union and classified as an antihypertensive drug. The product is intended for use under medical supervision to manage conditions such as high blood pressure and certain types of heart failure. Trandolapril blocks the conversion of angiotensin I to angiotensin II, helping to relax blood vessels.

Gopten, containing trandolapril, is used in clinical practice for several cardiovascular indications.

- Treatment of essential hypertension (high blood pressure). - Management of chronic heart failure to improve symptoms and reduce hospitalizations. - Adjunct therapy after myocardial infarction to lower risk of subsequent cardiac events. - Use in patients with left ventricular dysfunction where ACE inhibition is indicated. - May be prescribed as part of combination therapy with diuretics or other antihypertensive agents.

Side effects reported with trandolapril vary in frequency and severity.

Common: - Cough. - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue. - Nausea or mild gastrointestinal upset.

Serious: - Angioedema (swelling of face, lips, tongue, or throat). - Significant drop in blood pressure (hypotension). - Acute kidney injury or worsening renal function. - Hyperkalemia (elevated blood potassium).

Before starting Gopten, healthcare providers should evaluate several safety considerations.

- Assess renal function and serum electrolytes, especially potassium levels. - Review history of angioedema, cough, or hypersensitivity to ACE inhibitors. - Use cautiously in patients with volume depletion, low blood pressure, or on diuretics. - Avoid in pregnancy; trandolapril is contraindicated in the second and third trimesters. - Monitor blood pressure regularly after initiating therapy or adjusting the dose. - Consider dose adjustment in elderly patients or those with hepatic impairment.

Trandolapril may interact with other medicines, influencing its effectiveness or safety.

Avoid: - Concomitant use with aliskiren in patients with diabetes or renal impairment. - Potassium‑sparing diuretics or potassium supplements that can cause hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen) that may reduce antihypertensive effect and impair renal function.

Use with caution: - Other antihypertensive agents (beta‑blockers, calcium channel blockers) may increase risk of hypotension. - Lithium, as ACE inhibitors can raise lithium levels. - Diuretics, especially loop or thiazide types, may enhance blood pressure lowering.